LAKE FOREST, Calif.--(BUSINESS WIRE)--I-Flow Corporation (NASDAQ:IFLO - News) has commenced a lawsuit against Apex Medical Technologies, Inc. and its president, Mark McGlothlin, for infringing I-Flow’s United States Patent No. 5,284,481 and misappropriating I-Flow’s valuable trade secrets. The legal action states the Solace Pump was developed using I-Flow’s secret information and infringes I-Flow’s patent.
Recently, Judge Sabraw of the United States District Court for the Southern District of California interpreted the patent claims in a manner consistent with I-Flow’s position in the case. Thus, I-Flow will now ask the Judge to rule, as a legal matter, that Apex and McGlothlin have infringed the patent. I-Flow is also vigorously moving forward in the case to protect its valuable trade secrets.
In separate actions, I-Flow has sued two distributors of the Solace Pump and will continue to seek enforcement of its intellectual property rights against entities and individuals who make, use, sell, or offer to sell the Solace Pump.
About I-Flow
I-Flow Corporation (www.IFLO.com) is improving surgical outcomes by designing, developing and marketing technically advanced, low cost delivery systems and innovative surgical products for post-surgical pain relief and surgical site care.
“Safe Harbor” Statement
Statements by the Company in this press release and in other reports and statements released by the Company are and will be forward-looking in nature and express the Company’s current opinions about trends and factors that may impact future operating results. Statements that use words such as “may,” “will,” “should,” “believes,” “predicts,” “estimates,” “projects,” “anticipates” or “expects” or use similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to material risks, assumptions and uncertainties, which could cause actual results to differ materially from those currently expected, and readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, the Company undertakes no obligation to publish revised forward-looking statements to reflect the occurrence of unanticipated or subsequent events. Readers are also urged to carefully review and consider the various disclosures made by the Company in this press release that seek to advise interested parties of the risks and other factors that affect the Company’s business. Interested parties should also review the Company’s reports on Forms 10-K, 10-Q and 8-K and other reports that are periodically filed with or furnished to the Securities and Exchange Commission. The risks affecting the Company’s business include, among others: physician acceptance of infusion-based therapeutic regimens; implementation of the Company’s direct sales strategy; successful integration of the Company’s recent acquisition of AcryMed Incorporated and further development and commercialization of AcryMed’s technologies; dependence on the Company’s suppliers and distributors; the Company’s continuing compliance with applicable laws and regulations, such as the Medicare Supplier Standards and the Food, Drug and Cosmetic Act, and Medicare’s and the FDA’s concurrence with management’s subjective judgment on compliance issues; the reimbursement system currently in place and future changes to that system; product availability, acceptance and safety; competition in the industry; technological changes; intellectual property challenges and claims; economic and political conditions in foreign countries; currency exchange rates; inadequacy of booked reserves; potential non-cash purchase accounting adjustments associated with the AcryMed acquisition; and reliance on the success of the home health care industry. All forward-looking statements, whether made in this press release or elsewhere, should be considered in context with the various disclosures made by the Company about its business.
Contact:
Investor Contact: Berkman Associates Neil Berkman, 310-826-5051 info@BerkmanAssociates.com or Company Contact: I-Flow Corporation James R. Talevich, Chief Financial Officer 949-206-2700 www.iflo.com
Source: I-Flow Corporation
